Prof Salomon Manier speaks to ecancer at ASCO 2024 about safety results from the phase 3 MajesTEC-7 study in patients with transplant ineligible/not intended newly diagnosed multiple myeloma (NDMM).

He explains that the 26 enroled saw a favourable safety profile from the use of the bispecific antobodies - teclistamab, daratumumab and lenalidomide (Tec-DR).

Prof Manier reports that no grade 3 cytokine release syndrome was observed with the overall safety profile as expected with no new safety signals.